论文部分内容阅读
[目的]评价白细胞介素6(IL-6)、C反应蛋白(CRP)、乳酸脱氢酶(LDH)、β2微球蛋白(β2-MG)作为多发性骨髓瘤(MM)患者疗效和预后判断指标的价值。[方法]将17例MMⅢ期患者在中西医结合治疗过程中的110组实验室数据进行线性相关分析,并比较其中8例治疗前后各项指标的水平变化。[结果]治疗后IL-6、CRP、β2-MG、CRE、Urea、瘤细胞百分比(BMPC)、本周蛋白较治疗前下降(P<0.05);IL-6与CRP、LDH与β2-MG、LDH与本周蛋白、β2-MG与Urea、β2-MG与BMPC有非常显著相关性(P<0.01,|r|>0.45),IL-6与Ca有显著相关性(P<0.05,|r|>0.45)。A、B亚型间β2-MG差异非常显著(P<0.01),但其与BMPC相关性有统计学意义(P<0.05,|r|>0.45)。[结论]IL-6、CRP、β2-MG适合作为MMⅢ期患者疗效和预后的判断指标。
[Objective] To evaluate the efficacy and prognosis of patients with multiple myeloma (MM), including interleukin 6 (IL 6), C reactive protein (CRP), lactate dehydrogenase (LDH) and β 2 microglobulin Judge the value of the indicator. [Method] The linear correlation analysis of 110 laboratory data of MM Ⅲ phase during the course of TCM and WM was made, and the changes of the indexes before and after treatment were compared among 8 cases. [Results] After treatment, the levels of IL-6, CRP, β2-MG, CRE, Urea and the percentage of tumor cells in this week were lower than those before treatment (P <0.05) (P <0.01, | r |> 0.45), there was a significant correlation between IL-6 and Ca (P <0.05, | r |> 0.45). The difference of β2-MG between A and B subtypes was significant (P <0.01), but there was a significant correlation with BMPC (P <0.05, | r |> 0.45). [Conclusion] IL-6, CRP and β2-MG are suitable indicators for evaluating the curative effect and prognosis of patients with MM Ⅲ.